Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Other Non Operating Income came in at $1000.0 in Q1 2026, up 100.43% year-on-year from $498.92 in Q1 2025, and up 100.06% quarter-over-quarter from -$1.7 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $1000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 100.43% year-over-year to $1000.0 in Q1 2026; TTM through Mar 2026 was $232000.0, a 136.94% increase from a year earlier, with the FY2023 full-year figure at $542000.0, up 125.19% from the prior year.
- Other Non Operating Income climbed to $1000.0 in Q1 2026 per LCTX's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.7 million in Q2 2025 and bottomed at -$1.9 million in Q2 2022.
- The 5-year median for Other Non Operating Income is -$101500.0 (2022), against an average of -$184000.0.
- Biggest YoY gain for Other Non Operating Income was 543.92% in 2025; the steepest drop was 8668.42% in 2025.
- Year by year, Other Non Operating Income stood at $398000.0 in 2022, then slumped by 100.5% to -$2000.0 in 2023, then tumbled by 850.0% to -$19000.0 in 2024, then tumbled by 8668.42% to -$1.7 million in 2025, then surged by 100.06% to $1000.0 in 2026.
- Per Business Quant, the three latest LCTX Other Non Operating Income figures stand at $1000.0 (Q1 2026), -$1.7 million (Q4 2025), and $219000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | -1.67 Mn |
| Sep 30, 2025 | 219,000.00 |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | -231,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Jun 30, 2024 | -378,000.00 |
| Mar 31, 2024 | -354,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -497,000.00 |
| Mar 31, 2023 | 457,000.00 |
| Dec 31, 2022 | 398,000.00 |
| Sep 30, 2022 | -475,000.00 |
| Jun 30, 2022 | -1.89 Mn |
| Mar 31, 2022 | -184,000.00 |
| Dec 31, 2021 | 963,000.00 |
| Sep 30, 2021 | 393,000.00 |
| Jun 30, 2021 | 523,000.00 |
| Mar 31, 2021 | -1.68 Mn |